Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.43 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343622 | 0.84 | HPGD (0.54) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL8495322 | 0.83 | HPGD (0.50) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL27201505 | 0.83 | ALDH1A1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1892198 | 0.83 | HPGD (0.53) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL18692507 | 0.82 | DPP4 (0.51) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL18692506 | 0.82 | DPP4 (0.51) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL5341723 | 0.81 | HPGD (0.54) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL13666467 | 0.81 | EPHX1 (0.49) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL5946873 | 0.80 | HPGD (0.50) | HPGDRECQLEPHX1DPP4USP2 | |
| SCHEMBL25522993 | 0.80 | HPGD (0.50) | HPGDRECQLEPHX1DPP4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4308576-B1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4308576-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-116981674-A | Novel thiazolopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| EP-1192133-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6358979-B1 | FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1171122-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1165473-A1 | PROCESS FOR PREPARING 2,6-DIALKYLNAPHTALENE | KABUSHIKI KAISHA KOBE SEIKO SHO (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6248755-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076511-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076514-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000061529-A1 | PROCESS FOR PREPARING 2,6-DIALKYLNAPHTALENE | KABUSHIKI KAISHA KOBE SEIKO SHO (JP) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | NDUFS3, FOXM1, MT-ND1 | HPGD 2371/4885RECQL 671/4885EPHX1 2659/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HPGD 2691/4885RECQL 168/4885EPHX1 1387/4885 |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | HPGD 1418/4885RECQL 420/4885EPHX1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.